Usted buscó: doxorubicin (Maltés - Inglés)

50 mg doxorubicin hcl
50 mg doxorubicin hcl

liposomali doxorubicin hydrochloride
liposomal doxorubicin hydrochloride

fjala myocet doxorubicin hcl
myocet doxorubicin hcl vial

- vincristine, vinblastine u doxorubicin.
- vincristine, vinblastine and doxorubicin.

taxotere użat flimkien ma’ doxorubicin
taxotere in combination with doxorubicin

doxorubicin jista’ jikkawżaw kardjotossiċità.
doxorubicin can cause cardiotoxicity.

doxorubicin u cisplatin) (n=196)
paclitaxel arm (n=262)

docetaxel kabi użat flimkien ma’ doxorubicin
docetaxel kabi in combination with doxorubicin

docetaxel winthrop użat flimkien ma’ doxorubicin
docetaxel winthrop in combination with doxorubicin

is-sustanza attiva hi doxorubicin hydrochloride.
the active substance is doxorubicin hydrochloride.

doxorubicin u cyclophosphamide ingħataw flimkien kif ġej:
doxorubicin and cyclophosphamide were administered concurrently as follows:

dan fih is- sustanza attiva doxorubicin hydrochloride.
it contains the active substance doxorubicin hydrochloride.

Żid il-liposomi bil-ph irrangat għal doxorubicin
add ph-adjusted liposomes to doxorubicin

258 pazjent li ħadu docetaxel flimkien ma’ doxorubicin.
258 patients who received docetaxel in combination with doxorubicin.

- is- sustanza attiva hi doxorubicin hcl, 50 mg.
- the active substance is doxorubicin hcl, 50 mg.

tibdlux ma' formulazzjonijiet oĦrajn ta' doxorubicin hydrochloride.
do not use interchangeably with other formulations of doxorubicin hydrochloride.

doxorubicin u anthracyclines oħrajn jistgħu jikkaġunaw tossiċità kardijaka.
doxorubicin and other anthracyclines can cause cardiotoxicity.

huwa magħruf li doxorubicin huwa eliminat prinċipalment mill-fwied.
doxorubicin is known to be eliminated in large part by the liver.

docetaxel winthrop 75 mg/ m² użat flimkien ma ’ doxorubicin:
13 docetaxel winthrop 75 mg/ m² in combination with doxorubicin

taxotere użat flimkien ma’ doxorubicin u cyclophosphamide: terapija miżjuda
taxotere in combination with doxorubicin and cyclophosphamide: adjuvant therapy